DB:HDP1

Stock Analysis Report

Executive Summary

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has Arrowhead Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HDP1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

14.5%

HDP1

-1.6%

DE Biotechs

0.8%

DE Market


1 Year Return

261.1%

HDP1

-8.9%

DE Biotechs

9.0%

DE Market

Return vs Industry: HDP1 exceeded the German Biotechs industry which returned -8.9% over the past year.

Return vs Market: HDP1 exceeded the German Market which returned 9% over the past year.


Shareholder returns

HDP1IndustryMarket
7 Day14.5%-1.6%0.8%
30 Day41.7%-1.5%6.3%
90 Day53.2%-8.3%14.4%
1 Year261.1%261.1%-8.7%-8.9%12.4%9.0%
3 Year917.5%917.5%49.7%47.8%25.6%14.5%
5 Year767.1%767.1%-1.5%-4.6%41.0%21.8%

Price Volatility Vs. Market

How volatile is Arrowhead Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Arrowhead Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

86.85x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HDP1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HDP1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HDP1 is poor value based on its PE Ratio (86.9x) compared to the Biotechs industry average (29.9x).

PE vs Market: HDP1 is poor value based on its PE Ratio (86.9x) compared to the German market (19.9x).


Price to Earnings Growth Ratio

PEG Ratio: HDP1 is poor value based on its PEG Ratio (3.3x)


Price to Book Ratio

PB vs Industry: HDP1 is overvalued based on its PB Ratio (18.1x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Arrowhead Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

26.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HDP1's forecast earnings growth (26% per year) is above the savings rate (0.2%).

Earnings vs Market: HDP1's earnings (26% per year) are forecast to grow faster than the German market (12.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HDP1's revenue (19.9% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: HDP1's revenue (19.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HDP1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Arrowhead Pharmaceuticals performed over the past 5 years?

25.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HDP1 has high quality earnings.

Growing Profit Margin: HDP1's current net profit margins (33.3%) are higher than last year (-400.1%).


Past Earnings Growth Analysis

Earnings Trend: HDP1 has become profitable over the past 5 years, growing earnings by 25.9% per year.

Accelerating Growth: HDP1 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: HDP1 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: HDP1's Return on Equity (20.2%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Arrowhead Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: HDP1's short term assets ($244.5M) exceeds its short term liabilities ($87.1M)

Long Term Liabilities: HDP1's short term assets (244.5M) exceeds its long term liabilities (24.1M)


Debt to Equity History and Analysis

Debt Level: HDP1 is debt free.

Reducing Debt: HDP1 has no debt compared to 5 years ago when its debt to equity ratio was 0.03%.

Debt Coverage: HDP1 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: HDP1 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: HDP1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if HDP1's debt is covered by short term assets.


Next Steps

Dividend

What is Arrowhead Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate HDP1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HDP1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HDP1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HDP1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HDP1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Arrowhead Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

8.9yrs

Average management tenure


CEO

Chris Anzalone (50yo)

11.9yrs

Tenure

US$1,619,901

Compensation

Dr. Christopher R. Anzalone, also known as Chris, Ph.D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD1.62M) is below average for companies of similar size in the German market ($USD2.62M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Management Age and Tenure

8.9yrs

Average Tenure

54yo

Average Age

Experienced Management: HDP1's management team is seasoned and experienced (8.9 years average tenure).


Board Age and Tenure

9.3yrs

Average Tenure

60yo

Average Age

Experienced Board: HDP1's board of directors are considered experienced (9.3 years average tenure).


Insider Trading

Insider Buying: HDP1 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$515,84528 Sep 19
Christopher Anzalone
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares20,000
Max PriceUS$25.79
SellUS$4,947,13612 Sep 19
Michael Perry
EntityIndividual
Role
Lead Director
Independent Lead Director
Shares185,000
Max PriceUS$27.28
SellUS$430,77728 Jun 19
Mauro Ferrari
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares17,756
Max PriceUS$24.26
SellUS$667,87929 May 19
Patrick O'Brien
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares30,000
Max PriceUS$22.26
SellUS$858,94705 Apr 19
Christopher Anzalone
EntityIndividual
Role
Chief Executive Officer
CEO, President & Director
Shares50,000
Max PriceUS$17.18
SellUS$109,43811 Jan 19
William Waddill
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,500
Max PriceUS$12.88

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.


Management Team

  • Jane Davidson

    Head of Human Resources & Administration

    • Tenure: 0yrs
  • Bruce Given (65yo)

    Chief Operating Officer

    • Tenure: 8.1yrs
    • Compensation: US$1.55m
  • Mark Davis

    Founder and Founder & Director of Insert Therapeutics Inc & Calando

    • Tenure: 0yrs
  • Chris Anzalone (50yo)

    CEO, President & Director

    • Tenure: 11.9yrs
    • Compensation: US$1.62m
  • Howard Lovy

    Director of Communications

    • Tenure: 14.3yrs
  • Ken Myszkowski (53yo)

    Chief Financial Officer

    • Tenure: 9.8yrs
    • Compensation: US$853.02k
  • James Hamilton

    Head of Clinical Development & VP

    • Tenure: 0yrs
  • Susan Boynton

    Senior Vice President of Regulatory Affairs

    • Tenure: 0.2yrs
  • Patrick O'Brien (55yo)

    General Counsel

    • Tenure: 4.9yrs
    • Compensation: US$823.30k
  • Vincent Anzalone

    Head of Investor Relations & VP

    • Tenure: 0yrs

Board Members

  • Doug Given (67yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$189.15k
  • Mike Perry (60yo)

    Independent Lead Director

    • Tenure: 0yrs
    • Compensation: US$178.65k
  • Mark Davis

    Founder and Founder & Director of Insert Therapeutics Inc & Calando

    • Tenure: 0yrs
  • Chris Anzalone (50yo)

    CEO, President & Director

    • Tenure: 11.9yrs
    • Compensation: US$1.62m
  • Will Waddill (62yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$131.38k
  • Ching-Lung Lai

    Member of Hepatitis B Clinical Advisory Board

    • Tenure: 0yrs
  • Robert Gish

    Chairman of Hepatitis B Clinical Advisory Board

    • Tenure: 0yrs
  • Mauro Ferrari (60yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$99.99k
  • Stephen Locarnini

    Member of Hepatitis B Clinical Advisory Board

    • Tenure: 0yrs
  • Johnson Lau

    Member of Hepatitis B Clinical Advisory Board

    • Tenure: 0yrs

Company Information

Arrowhead Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arrowhead Pharmaceuticals, Inc.
  • Ticker: HDP1
  • Exchange: DB
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.092b
  • Listing Market Cap: US$3.716b
  • Shares outstanding: 95.30m
  • Website: https://arrowheadpharma.com

Number of Employees


Location

  • Arrowhead Pharmaceuticals, Inc.
  • 225 South Lake Avenue
  • Suite 1050
  • Pasadena
  • California
  • 91101
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARWRNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJan 2004
HDP1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2004
0HI3LSE (London Stock Exchange)YesCommon StockGBUSDJan 2004

Biography

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate fo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/12 20:32
End of Day Share Price2019/11/12 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.